IRLAB Therapeutics AB

Rooted in Nobel Prize-winning research, IRLAB is working on the next breakthrough in Parkinson’s disease  🌟    IRLAB’s unique resource-efficient research method, the Integrative Screening Process (ISP), is based on the research of the Nobel Laureate, Arvid Carlsson, who revolutionized our understanding of brain chemistry and paved the way for modern treatments of neurological disorders.       Arvid Carlsson’s groundbreaking research in the 1950s led to the discovery of dopamine as a crucial neurotransmitter, fundamentally changing our approach to treating Parkinson's disease. In 2000, Carlsson was awarded the Nobel Prize in Physiology or Medicine for his monumental contributions to neuroscience.       Arvid Carlsson's research led to the establishment of levodopa as the primary treatment for Parkinson's disease. We at IRLAB are working on the next breakthrough to reduce the disease's burden for Parkinson’s patients.  Follow us for more insights on our work discovering and developing novel treatments for #parkinsonsdisease    #irlabtherapeutics #CNS #drugdiscovery #drugdevelopment   

Don't miss Kristina Torfgårds presentation at the ABG Sundal Collier Investor Days! Available via the link below. https://lnkd.in/dPnPdN7W #parkinsonsdisease #irlabtherapeutics #drugdiscovery #innovation

On December 3rd, Kristina Torfgård, CEO, and Ross Nicholas Waters, EVP, Head of R&D, presented IRLAB at Redeye Technology & Life Science Day in Stockholm. ⭐ In case you missed it, the interview is available here: https://lnkd.in/dbeaZGYb Redeye AB #irlabtherapeutics #drugdiscovery #parkinsonsdisease #drugdevelopment #lifesciences #innovation #investors

IRLAB today announced that the company will present at the Redeye AB Technology & Life Science Day 2024 on Tuesday, December 3, 2024, in Stockholm, Sweden. Kristina Torfgård, CEO, and Ross Nicholas Waters, EVP, Head of R&D, will participate in the event. The company will give a 2-minute pitch and then participate in a Q&A session at 13:20-13:40 CET on December 3, 2024. 📍 This event is held at Sergelkonferensen, Mäster Samuelsgatan 42, Stockholm, and is live-streamed. More information can be found on the event webpage at: https://lnkd.in/dA_bNAqr

Be sure not to miss our CEO Kristina Torfgård's presentation at Biostock Life Science Summit 2024. #parkinsonsdisease #irlabtherapeutics #drugdiscovery #innovation BioStock - Connecting Innovation and Capital https://lnkd.in/dzvgy87F

Did you know that psychosis is common in people with late-stage Parkinson’s disease ?   Approximately 20-40% of people with late-stage Parkinson’s will eventually develop psychosis associated with the disease. Psychosis can vary from seeing things that aren’t there (hallucinations) to believing things that are not true (delusions) or severe confusion (disordered thinking). These symptoms tend to become more frequent and worsen over time, and the person’s insight may ultimately be lost.    Psychosis severely impairs the quality of life for people with Parkinson’s disease and their families. Managing the condition presents a unique clinical challenge, as many antipsychotic agents are known to worsen the basic symptoms of Parkinson’s disease.    IRLAB's pipeline currently includes five drug candidates, all of which have the potential to revolutionize the treatment of Parkinson's disease. Four of them target the symptoms that have the greatest impact on function and quality of life, such as psychosis. The fifth is being developed as a new treatment for the basic symptoms of Parkinson’s.    Follow us to learn more about Parkinson’s disease and our pipeline!    #parkinsonsdisease #psychosis #irlabtherapeutics #drugdiscovery #innovation   

IRLAB's CEO, Kristina Torfgård, will present IRLAB to potential partners and specialist investors in life science at the seventh edition of BioStock - Connecting Innovation and Capital Life Science Summit. The event will take place on November 20-21 in Lund, Sweden. ⭐ Kristina will present the company at 14:45 CET on November 20. IRLAB's presentation will be filmed and made available afterward on Biostock's website and social media. More information about the meeting: https://lnkd.in/evGSkHq9 #parkinsonsdisease

IRLAB is at #BioEurope. Do you want to know more about the company and our pipeline in Parkinson's disease? Contact CEO Kristina Torfgård or follow us here on LinkedIn. #irlabtherapeutics #drugdiscovery #parkinsonsdisease #drugdevelopment #lifesciences

IRLAB är på #BioEurope i Stockholm. Vill du veta mer om bolaget och vår pipeline inom Parkinsons? Hör av dig till vd Kristina Torfgård eller följ oss här på LinkedIn. #irlabtherapeutics #drugdiscovery #parkinsonsdisease #drugdevelopment #lifesciences

IRLAB today announced that the company’s interim report for the period January-September 2024, has been published. A presentation of the Q3 interim report will be held through a digital webcast on Wednesday, October 30, 2024, at 10.00 CET. The presentation will be held in English, followed by a Q&A session. Access via link: https://lnkd.in/dCdWspDD Read the full report on the IRLAB website: https://lnkd.in/dkr8NADn